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Summary
Background.— Elevated blood pressure is one of the most important modiﬁable risk factors for
cardiovascular diseases.
Aim.— To evaluate blood pressure management in Côte d’Ivoire.
Methods.— A retrospective study was conducted among 2575 hypertensive patients from the
Institute of Cardiology of Abidjan, who were followed for at least 10 years, between January
2000 and December 2009.
Results.— The patients’ mean age± standard deviation was 59.1± 12.5 years; 54.3% were
women. At ﬁrst presentation, hypertension was stage 1 in 21.7%, stage 2 in 32.3% and stage 3
in 46.0% of patients. According to the European guidelines’ stratiﬁcation of the cardiovascular
risk-excess attributable to high blood pressure, 46.7% had a very high added risk, 37.8% had
a high added risk and 14.9% had a low-to-moderate added risk. Pharmacological therapy was
prescribed in 97.8% of patients; more than 66% were receiving at least two antihypertensive
drugs, including ﬁxed-dose combination drugs. The most common agents used were diuretics
(59.7%) followed by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
(59.6%). The most common agents for monotherapy were calcium antagonists. When two or
Abbreviations: ESC, European Society of Cardiology; ESH, European Society of Hypertension; ICA, Institute of Cardiology of Abidjan
institut de cardiologie d’Abidjan); RAS, renin-angiotensin system; SD, standard deviation; SSA, Sub-Saharan Africa.
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more drugs were used, diuretics and angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers were most commonly used. Blood pressure control was achieved in 43.7% of
cases.
Conclusion.— In our series, severe hypertension with high added risk or very high added risk
was very common. Treatment —mostly diuretics and angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers— required at least two antihypertensive drugs to meet the
recommended blood pressure target.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé
Introduction.— L’hypertension artérielle constitue un des principaux facteurs de risque car-
diovasculaires. Cette étude a été entreprise pour évaluer sa prise en charge en consultation
externe de l’Institut de cardiologie d’Abidjan.
Méthodes.— Il s’agissait d’une étude rétrospective, incluant les hypertendus ayant au moins
un an de suivi.
Résultats.— Il s’agissait de 2575 patients ayant un âge moyen de 59,1± 12,5 ans et dont 54,3 %
étaient de sexe féminin. À la consultation initiale, l’hypertension artérielle était de grade
1 dans 21,7 %, de grade 2 dans 32,3 % et de grade 3 dans 46,0 %. Le risque cardiovasculaire évalué
selon les recommandations de la Société européenne de cardiologie et la Société européenne
d’hypertension artérielle était très élevé dans 46,7 %, élevé dans 37,8 % et faible ou modéré
dans 14,9 %. Un traitement médicamenteux a été prescrit dans 97,8 %. Plus de 66% des patients
avaient au moins deux antihypertenseurs incluant les associations ﬁxes. Les antihypertenseurs
les plus prescrits étaient les diurétiques (59,7 %) suivis des inhibiteurs de l’enzyme de conver-
sion ou de l’angiotensine 2 (59,6 %). Quand il s’agissait d’une monothérapie, les antagonistes
calciques étaient les plus utilisés. En revanche, les associations médicamenteuses ont pris en
compte surtout les diurétiques et les inhibiteurs de l’enzyme de conversion ou de l’angiotensine
2. La tension artérielle a été équilibrée chez 43,7 % des patients.
Conclusion.— Il s’agissait surtout d’hypertension artérielle sévère avec un risque cardio-
vasculaire élevé. Pour atteindre l’objectif tensionnel recommandé, une polythérapie a été
nécessaire, utilisant surtout les diurétiques et les inhibiteurs de l’enzyme de conversion ou de
l’angiotensine 2.
Tou
a
t
f
h
c
t
s
i
t
a
M
W
p
p
2
(
w
r© 2011 Elsevier Masson SAS.
Background
Hypertension is an important worldwide public health chal-
lenge because it is one of the most common chronic
conditions [1,2]. In a worldwide survey, 26.4% of the adult
population in 2000 had hypertension and 29.2% were pro-
jected to have this condition by 2025. The estimated total
number of adults with hypertension in 2000 was 972 million
and 639 million in economically developing countries [1].
The prevalence of hypertension in Sub-Saharan Africa (SSA)
is between 12.5% and 26.9% [3]. In 2005 the World Health
Organization’s stepwise approach to the surveillance of non-
communicable disease risk factors established a prevalence
of hypertension in Côte d’Ivoire of 21.7% [4].
Hypertension is a major risk factor for cardiovascular
disease [5—7]; it remains an important cause of coronary
heart disease, cerebrovascular disease, peripheral artery
disease and heart failure [8]. The 2002 World Health Report
estimated that around 11% of the entire disease burden in
developed countries was caused by raised blood pressure,
and that more than 50% of coronary heart diseases and
almost 75% of strokes arose as a result of elevated systolic
blood pressure [9]. In SSA, the mortality among patients hos-
pitalized for hypertension-related disorders is over 20% [10].
Unfortunately the particular context of SSA, with its poverty
h
a
cs droits réservés.
nd illiteracy, contributes to the low awareness and subop-
imal control and treatment of hypertension [11,12]. These
acts underscore that screening and effective treatment for
ypertension should be given higher priority in health poli-
ies in this region. It was in this context that we undertook
his study at the Institute of Cardiology of Abidjan (ICA), the
ingle university hospital managing cardiovascular diseases
n Côte d’Ivoire. The study aimed to describe characteris-
ics, risk factors, treatment and blood pressure control in
dult hypertensive patients.
ethods
e undertook a retrospective descriptive study involving
atients seen in outpatient clinics at the ICA. The study
eriod spans 10 years, between January 2000 and December
009. The study population comprised hypertensive adults
aged at least 18 years) with a regular follow-up at the ICA
ithin 1 year. This series included patients who had been
eceiving initial treatment upon referral to our centre.
We used the standard deﬁnition and classiﬁcation of
ypertension of the European Society of Hypertension (ESH)
nd the European Society of Cardiology (ESC) [7]. The data
ollected were age, sex and level of blood pressure at
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angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers) (59.6%), calcium antagonists (25.2%),
beta-blockers (23.9%) and centrally-acting sympatholytics
Table 1 Other cardiovascular risk factors and organ
damage.
% of patients
Other cardiovascular risk factors
Dyslipidaemia 31.7
Diabetes mellitus 12.2
Current smoking 9.1
Obesity 12.7
Organ damage
None (n = 665) 25.8
One organ (58.7%, n = 1512)
Cardiovascular 48.9
Kidney 7.0
Cerebral 2.8
More than one organ (15.5%, n = 398)
Cardiovascular + kidney 10.860
nitial presentation and, during follow-up, the coexistence
f other cardiovascular risk factors, the impact of hyper-
ension and treatment modalities. The following additional
ardiovascular risk factors were documented when present:
urrent smoking, dyslipidaemia, diabetes and obesity. Obe-
ity was deﬁned as body mass index greater than 30 kg/m2.
aist circumference was recorded when available. Dys-
ipidaemia was deﬁned according to our biochemistry
aboratory standard (total cholesterol > 200mg/dL or low-
ensity lipoprotein cholesterol > 140mg/dL or high-density
ipoprotein cholesterol < 40 g/L). Diabetic patients were
nformed and treated for diabetes according to standard
linical practice. New diabetic patients detected at the
CA were diagnosed based on the standard value in our
aboratory (fasting plasma glucose > 126mg/dL on repeated
easurement). The overall management of diabetes was
oordinated by the individual patient’s physician and not
y the cardiology staff of the ICA.
Assessment of the impact of hypertension systemati-
ally included electrocardiography and plasma creatinine
easurement. All strokes were documented by a brain
omputerized tomography scan. Echocardiography was fre-
uently performed and the results were included in the data
ollection. Finally, if other tests were seldom performed
e.g. albuminuria, microalbuminuria, fundoscopy and 24-
our ambulatory blood pressure) they were not used for
nalysis.
The ESH/ESC categorization of total risk as low, moder-
te, high and very high added risk has the merit of simplicity
nd was therefore chosen for risk stratiﬁcation [7]. In addi-
ion, we focused on the evolution of blood pressure during
ollow-up. Blood pressure control was deﬁned as a treated
ystolic blood pressure less than 140mmHg and diastolic
lood pressure less than 90mmHg, and was ascertained by
irect measurement of blood pressure.
Data analysis was conducted using Statistical Package
or Social Sciences (SPSS) software, version 17. Univari-
te analysis was performed for signiﬁcant associations. A
value≤ 0.05 was considered for statistical signiﬁcance.
esults
here were 2575 patients (54.3% women) with a mean
ge± standard deviation (SD) of 59.1± 12.5 years (range:
8—89 years). At ﬁrst presentation, mean blood pressure
as 169/102mmHg (range: 120/80 to 250/130mmHg), with
nappropriate control in 90.5% of patients. The hypertension
as classiﬁed as stage 1 in 21.7%, stage 2 in 32.3% and stage
in 46.0% of patients. Blood pressure levels were similar in
ll age groups (P = 0.18). Stage 3 hypertension was the most
ommon in all age categories (Fig. 1).
Overall, patients had been diagnosed with hyperten-
ion for a mean duration± SD of 8.8± 5.3 years (range:
—15 years) at the time of their initial assessment in our
linics. The mean follow-up duration± SD in the ICA was
.3± 4.1 years (range: 1—18 years). Other risk factors and
rgan damage are reported in Table 1. Cardiovascular
omplications were left ventricular hypertrophy (44.4%,
= 1144), heart failure (16.2%, n = 417), coronary artery
isease (5.2%, n = 133), arrhythmia (4.9%, n = 127) and
eripheral arterial disease (0.5%, n = 13). Echocardiographyigure 1. The distribution of hypertensive patients by age and
ypertension stage at initial presentation.
as performed in 1182 patients (45.9%) and was normal
n 227 (19.2%). The recorded anomalies were left ven-
ricular diastolic dysfunction (35.6%, n = 421), hypertensive
ardiomyopathy (29.7%, n = 351) and minor lesions (slight
alve regurgitation, sclerosis, valvular calciﬁcation) (11.2%,
= 133). Cardiovascular risk stratiﬁcation according to the
uropean guideline for the management of arterial hyper-
ension is reported in Table 2. The very high added risk and
igh added risk categories were predominant at presenta-
ion in 46.7% and 37.8% of patients, respectively.
In addition to lifestyle changes, 97.8% of patients
eceived antihypertensive drugs. Among those receiving
reatment for high blood pressure, the most common
gents used were diuretics (59.7% of patients), followed
y blockers of the renin-angiotensin system (RAS) (eitherCardiovascular + cerebral 3.4
Kidney + cerebral 0.4
Cardiovascular + kidney + cerebral 0.9
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Table 2 Stratiﬁcation of the cardiovascular risk of patients, according to the risk stratiﬁcation recommended by the
European guideline for the management of arterial hypertension.
Other risk factors, OD
or disease
Blood pressure (mmHg) Total
Normal High normal Grade 1 HT Grade 2 HT Grade 3 HT
SBP
120—129 or
DBP 80—84
SBP
130—139 or
DBP 85—89
SBP
140—159 or
DBP 90—99
SBP
160—179 or
DBP
100—109
SBP ≥ 180
or DBP ≥
110
No risk factor 7 (0.3) 8 (0.3) 30 (1.2) 41 (1.6) 35 (1.4) 121 (4.7)
1—2 risk factors 34 (1.3) 43 (1.7) 78 (3.0) 77 (3.0) 211 (8.2) 443 (17.2)
3 or more risk factors, MS,
OD or diabetes
81 (3.1) 66 (2.6) 351 (13.6) 522 (20.3) 499 (19.4) 1519 (59.0)
Established cardiovascular or
renal disease
2 (0.1) 4 (0.2) 47 (1.8) 113 (4.4) 326 (12.7) 492 (19.1)
Total 124 (4.8) 121 (4.7) 506 (19.7) 753 (29.2) 1071 (41.6) 2575 (100)
Data are number (%). Low added risk (n = 107), moderate added risk (n = 277), high added risk (n = 974) and very high added risk (n = 1202).
DBP: diastolic blood pressure; HT: hypertension; MS: metabolic syndrome; OD: subclinical organ damage; SBP: systolic blood pressure.
Table 3 Type of drugs used.
% of patients
One drug (33.6%, n = 846)
Calcium antagonist 34.6
RAS-blocker 31.2
Diuretic 15.4
Beta-blocker 15.1
CAS 3.7
Two drugs (50.0%, n = 1259)
RAS-blocker + diuretic 66.2
Beta-blocker + diuretic 9.3
Beta-blocker + calcium antagonist 9.0
Diuretic + calcium antagonist 4.0
RAS-blocker + calcium antagonist 3.8
RAS-blocker + beta-blocker 3.0
CAS + (diuretic or RAS-blocker or calcium
antagonist or beta-blocker)
4.7
Three drugs (14.2%, n = 357)
RAS-blocker + diuretic + calcium antagonist 52.3
RAS-blocker + diuretic + beta-blocker 21.6
Diuretic + beta-blocker + calcium
antagonist
12.1
RAS-blocker + beta-blocker + calcium
antagonist
5.3
Other 8.7
Four drugs (2.1%, n = 53)
RAS-blocker + diuretic + calcium
antagonist + beta-blocker
63.0
RAS-blocker + diuretic + calcium
antagonist + CAS
24.0
Other 13.0
Five drugs (0.1%, n = 2)
RAS-blocker + diuretic + calcium
antagonist + beta-blocker + CAS
100(6.4%). Antihypertensive drugs were used as monotherapies
or in combination (Table 3). As a monotherapy, the most
frequently prescribed drug class was calcium antagonists
(34.6%) followed by RAS-blockers (31.2%). More than 66%
of patients being treated for hypertension were receiving
at least two antihypertensive drugs, including ﬁxed-dose
combination drugs. The most common combination of drugs
among those taking two agents was a RAS-blocker plus a
diuretic (66.2%), and among those taking three agents was
a RAS-blocker plus a diuretic plus a calcium antagonist
(52.3%).
Between the ﬁrst and last visits, systolic blood pres-
sure decreased by 20mmHg and diastolic blood pressure by
13mmHg. Hypertension was controlled in 43.7% of patients
despite detectible culprit factors inﬂuencing blood pressure
control (age, weight, body mass index and presence of left
ventricle hypertrophy; Table 4). The therapeutic approach
also had an impact on blood pressure control; the most
effective monotherapies were calcium antagonists followed
by diuretics, then beta-blockers and RAS-blockers (Table 5).
Finally, combination therapy, including the association of
RAS-blocker with a diuretic, produced a better reduction in
systolic blood pressure compared with other combinations
that excluded both RAS-blockers and diuretics (Table 5).
For statistical analysis, centrally-acting sympatholyt-
ics were ignored because of their infrequent use. Among
monotherapy regimens, there was a statistically signiﬁcant
difference between antihypertensive drugs in terms of low-
ering SBP: F = 13.868, P < 0.01; calcium antagonists were
the most effective compared with beta-blockers (P < 0.01),
RAS-blockers (P < 0.01) and diuretics (P < 0.01); second in
line came diuretics compared with beta-blockers (P < 0.01)
and RAS-blockers (P < 0.01); there were no statistically sig-
niﬁcant differences between the effects of RAS-blockers
and beta-blockers on SBP (P = 0.08). In contrast, there
were no statistically signiﬁcant differences between the
various antihypertensive classes in terms of reduction in
DBP (F = 0.11, P = 0.95). Among the polytherapy regimens,
patients who received a RAS-blocker + diuretic combination
CAS: centrally-acting sympatholytic.
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Table 4 Factors inﬂuencing blood pressure control.
Blood pressure controlled Blood pressure uncontrolled P
Age (years) 58.5± 12.5 59.7± 12.5 0.01
Male/female (n/n) 523/602 654/796 0.48
Weight (kg) 72.7± 15.3 78± 13.1 < 0.01
Waist (m) 1.66± 0.11 1.67± 0.09 0.85
Body mass index (kg/m2) 26.4± 4.19 28.4± 3.96 0.02
Diabetes 154 (13.7) 160 (11.0) 0.52
Left ventricle hypertrophy 711 (62.2) 433 (37.8) < 0.01
Data are mean± standard deviation or number (%) unless otherwise indicated.
Table 5 Change in blood pressure according to drugs used.
n Systolic blood pressure Diastolic blood pressure
Initial Final Difference Initial Final Difference
Monotherapy
Calcium antagonist 293 167.5± 28.7 130.9± 30.4 36.6± 36.4 99.4± 18.9 80.5± 15.6 18.9± 24.6
Diuretic 130 180.3± 29.2 145.7± 15 34.6± 30.9 105.1± 13.4 86.4± 11.7 18.7± 14.6
CAS 31 171.1± 15.3 137.3± 19.8 33.8± 19.0 108.4± 7.8 82.3± 9.2 26.1± 9.2
RAS-blocker 264 171± 20.5 146.2± 25.6 24.8± 33.7 104.5± 16.8 86.3± 13.5 18.2± 22.9
Beta-blocker 128 170.7± 17.9 153.4± 22.9 17.3± 22.2 107.7± 11.2 90.5± 12.7 17.1± 16.5
Polytherapy
RAS-blocker + diuretic 1145 165.9± 1.5 150.7± 23.0 15.2± 29.4 95.4± 15.8 87.9± 13.4 7.5± 20.9
Other 584 161.7± 23.2 151.3± 16.3 10.4± 36.3 95.8± 24.2 89± 13.5 6.8± 20.0
P < 0.01 0.33 < 0.01 0.23 0.02 0.24
Data are mean± standard deviation.
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had signiﬁcantly higher SBP at initiation of therapy (P < 0.01)
nd this combination was more effective at controlling SBP
ompared with other combination therapies (P < 0.01).
iscussion
he primary goal of treatment of the hypertensive patient
s to achieve the maximum reduction in the long-term total
isk of cardiovascular morbidity and mortality. This requires
reatment of all the reversible risk factors identiﬁed, includ-
ng smoking, dyslipidaemia, abdominal obesity or diabetes
7,13]. Antihypertensive treatment translates into signiﬁ-
ant reductions in cardiovascular morbidity and mortality
14—17].
We observed a blood pressure level that was too high
mong our patients; hypertension stage 3 was observed in
6% of patients. As has been previously described, it is sug-
ested that Black Africans present with more severe forms of
rterial hypertension and a greater risk of target organ dam-
ge [18—21]. Over 74% of our patients had organ damage.
urthermore, signiﬁcant comorbidities, such as diabetes,
ere found in 12.2%. All of this contributed to the important
ates of very high (46.7%) or high (37.8%) added cardiovascu-
ar risk that we observed. An Italian study using the ESH/ESC
lassiﬁcation for cardiovascular risk stratiﬁcation found a
o
b
r
bery high added risk in 9.7%, a high added risk in 19.8%,
moderate added risk in 23.7% and a low added risk in
6.8% of patients [22]. In a cross-sectional study of hyper-
ension conducted among civil servants in Accra (Ghana),
arget organ damage was present in 47.5% of the partic-
pants, with a 9.1% prevalence of diabetes [11]. Overall,
ncontrolled blood pressure remains the main factor for tar-
et organ damage, at highest extent in SSA compared with
estern countries [23].
The main beneﬁts of antihypertensive treatment are
lood pressure lowering per se, largely independent of the
rugs employed. Diuretics, beta-blockers, calcium antago-
ists and RAS-blockers can adequately lower blood pressure,
igniﬁcantly improving cardiovascular outcome [24]. All
hese drugs are considered suitable for the initiation
nd maintenance of treatment, either as monotherapy
r in combination therapeutic regimens. In our series,
onotherapy consisted mainly of calcium antagonists and
AS-blockers. Given the importance of organ damage in
ur cohort, these drugs were highly appropriate. Calcium
ntagonists, besides being effective for left ventricular
ypertrophy, appear beneﬁcial in slowing the progression
f carotid hypertrophy and atherosclerosis [25,26]. RAS-
lockers have been reported to be particularly effective in
educing left ventricular hypertrophy, in reducing microal-
uminuria and proteinuria, in preserving renal function and
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delaying renal disease [27—31]. This is also the reason
why diuretics, although the most prescribed drugs, were
most usually used in combination rather than alone in our
hypertensive patients. Although the overall beneﬁts/harm
of centrally-acting antihypertensive drugs remain unproven,
they were still used in our context [7]. They were mainly
used in adjunctive regimens. Centrally-acting drugs are less
expensive than other antihypertensive drugs, which repre-
sents a particular advantage in our context.
More than two-thirds of hypertensive patients are unsat-
isfactorily controlled with monotherapy, according to the
Joint National Committee VII report [13], as they require
two or more antihypertensive drugs. Our ﬁndings are consis-
tent with this report, as over 66% of our patients required
at least two drugs to achieve blood pressure control. The
combination drugs we used were commonly a RAS-blocker
plus a diuretic. Recommendations state that the drugs to be
combined should have different and complementary mech-
anisms of action. The blood pressure lowering effect of the
combination should be greater than that of the combina-
tion components, possibly also with a reduction in their
side effects. The combination should also have a greater
protective effect on organ damage. The combination of a
RAS-blocker plus a diuretic satisﬁes all these criteria [32].
In a previous short series, low compliance with antihyper-
tensive treatment was recorded among our patients [33].
The causes were numerous: no medical insurance, unem-
ployed patients, high cost of drugs and a high number of daily
tablets required (more than three), among other causes. A
population- and economics-speciﬁc context must be taken
into account when prescribing long-term medication. The
process of buying the drug can be complex, involving African
family solidarity. For instance, it is quite common that the
person purchasing the medication is a family member rather
than the patient.
We consider that the rate of blood pressure control was
very acceptable in our context (43%). Whereas our results
report data from the reference centre in Côte d’Ivoire, it
is inappropriate to extrapolate to a national level in Côte
d’Ivoire. This health problem is usually managed mostly by
a general practitioner, or by a local nurse in rural areas.
Given optimal conditions with appropriate management in a
referral centre, blood pressure control can be similar to that
reported in Western series (31—46% in Europe and 63% in the
USA) [34]. While studies from other African nations showed
lower blood pressure control (29% in Kenya [35]; 11.4% in
Ghana [11]), improvement in the rate of target blood pres-
sure attainment continues in England, for example, where
it rose from 46% in 2003 to 52% in 2006 [36].
Our data provide another line of evidence that diuretics
and calcium antagonists are optimal monotherapy choices
for the control of hypertension in Africans. As previously
demonstrated, RAS-blockers are less useful in treating
African hypertensive patients due to low plasma renin activ-
ity in this population [37—39]. Our observation supports
this, as RAS-blocker monotherapy led to poor blood pressure
control in our cohort. Fortunately, when associated with a
diuretic, the resulting blood pressure reduction improved.
We therefore suggest avoiding RAS-blockers as monother-
apy in the treatment of hypertension in Africans. When a
RAS-blocker is necessary due to known comorbidities, we
recommend its combination with a diuretic [27—31].563
tudy limitations
here were a number of limitations to this study. Firstly,
ther behavioural measures, such as increased physical
xercise, decreased obesity, cessation of smoking and limit-
ng alcohol consumption, are important for the control of
ypertension. In our retrospective study, such data were
ifﬁcult to document. In the same way, control of other mod-
ﬁable cardiovascular risk factors (diabetes, dyslipidaemia),
hich is essential in the management of hypertension, was
verlooked. Secondly, this cross-sectional study did not
ttempt to assess the occurrence of complications of hyper-
ension during the follow-up period. The main limitation
rom a methodological standpoint was that our study was
imited to cases with regular follow-up, which basically
xcluded patients who were unlikely to comply with med-
cation. The most regular hypertensive patients at the ICA
ere very likely to be aware of their illness and compliant
ith treatment, which may represent a bias in the selection
riteria.
onclusion
iven the appropriate social and medical environment, it is
ossible to achieve optimal blood pressure in Côte d’Ivoire,
imilar to that in economically wealthy Western countries.
his was particularly true in high-risk patients. Our data
hould encourage local and neighbouring authorities to plan
nd implement public health policies in this direction.
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